3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
38
Carcinoma, Renal Cell
12
Carcinoma, Non-Small-Cell Lung
12
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
8
Carcinoma, Merkel Cell
8
Uterine Cervical Neoplasms
7
Stomach Neoplasms
7
Colorectal Neoplasms
6
Carcinoma, Transitional Cell
6
Carcinoma, Hepatocellular
6
Small Cell Lung Carcinoma
5
Neoplasms
5
Kidney Neoplasms
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Esophageal Neoplasms
3
Breast Neoplasms
3
Urogenital Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Pancreatic Neoplasms
2
Neoplasms by Histologic Type
2
Microsatellite Instability
2
Mesothelioma, Malignant
2
Mesothelioma
2
Lymphoma
2
Lung Neoplasms
2
Gastrointestinal Neoplasms
2
Carcinoma, Squamous Cell
2
Interventions
Epoetin Alfa
3
Darbepoetin alfa
3
cobomarsen
2
Therapeutics
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Early Intervention, Educational
2
Antilymphocyte Serum
2
vandetanib
1
tirbanibulin
1
sargramostim
1
motesanib diphosphate
1
imetelstat
1
fludarabine phosphate
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
ethanolamine oleate
1
entrectinib
1
atezolizumab
1
Vorinostat
1
Trimethoprim, Sulfamethoxazole Drug Combination
1
Trimethoprim
1
Thiotepa
1
Sulfamethoxazole
1
Sucrose
1
Sodium Chloride
1
Sirolimus
1
Saline Solution, Hypertonic
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
atezolizumab
×
Dermatologic
×
Clear all
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled